Merck is one of the world’s leading pharmaceutical companies.
Merck reported full year 2025 worldwide sales of $65.0 billion — a 1.3% increase — driven by Keytruda at $31.7 billion, which now constitutes approximately 49% of total pharmaceutical sales. Merck occupies a strategically complex position: the world’s most commercially successful oncology drug is simultaneously the company’s greatest strength and its most significant strategic vulnerability. Keytruda’s patent expiration in 2028 and the anticipated entry of biosimilar competition will require the largest revenue replacement exercise in pharmaceutical history. WINREVAIR reached $1.4 billion in its first full year.
This report provides comprehensive strategic intelligence on Merck — covering strategic directions, financial performance, SWOT analysis, technological know-how, latest products and services, M&A, marketing tactics, and organization and management.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Financial performance 2023-2025
• SWOT analysis
• Technological know-how and key platforms
• Latest products, programs, and innovation pipeline
• M&A activity 2023-2025
• Marketing tactics and commercial strategy
• Organization and management
Table of Contents
1. Executive Summary
2. Strategic Directions
3. Financial Performance
4. SWOT Analysis
5. Technological Know-How
6. Latest Products and Services
7. M&A
8. Marketing Tactics
9. Organization and Management
10. Appendix
List of Tables
Table 1. Merck — Key Financial Metrics 2023-2025
Table 2. Merck — Revenue by Therapeutic Area 2023-2025
Table 3. Merck — Revenue by Geography 2023-2025
Table 4. Merck — R&D Investment 2023-2025
Table 5. Merck — SWOT Analysis
Table 6. Merck — Key Technology Platforms
Table 7. Merck — Top Products by Revenue 2025
Table 8. Merck — Late-Stage Pipeline 2025
Table 9. Merck — M&A Activity 2023-2025
Table 10. Merck — Key Management
Table 11. Merck — Strategic Priorities 2025-2030
